Research Article
Clinical Characteristics of Aldosterone- and Cortisol-Coproducing Adrenal Adenoma in Primary Aldosteronism
Table 1
Clinical data of A/CPA patients and pure APA patients.
| | A/CPA patients | Pure APA patients | value |
| | Number of cases | 22 | 392 | | | Age (years) | 40.32 ± 6.37 | 38.37 ± 7.76 | 0.1255 | | Age range (years) | 26–51 | 19–58 | | | Female, n (%) | 14, 63.64% | 219, 52.87% | 0.3252 | | BMI (kg/m2) | 25.45 ± 3.22 | 25.28 ± 3.44 | 0.8111 | | Tumor size (mm) | 24.50 ± 11.34 | 18.92 ± 7.98 | 0.0318 | | SBP (mmHg) | 181.4 ± 31.55 | 180.6 ± 26.57 | 0.8180 | | DBP (mmHg) | 108.2 ± 13.26 | 109.2 ± 14.87 | 0.7071 | | Duration of HT (years) | 11.91 ± 8.26 | 9.46 ± 7.30 | 0.1489 | | Stroke, n (%) | 3 (13.64%) | 22 (5.61%) | 0.1242 | | Heart disease, n (%) | 8 (36.36%) | 41 (10.46%) | 0.0003† | | CVE history, n (%) | 11 (50%) | 63 (16.07%) | <0.0001† | | Glucose intolerance/diabetes, n (%) | 13 (59.09%) | 85 (21.68%) | <0.0001† | | Lipid metabolic disorder, n (%) | 9 (40.91%) | 108 (27.55%) | 0.1757 | | Osteopenia/osteoporosis, n (%) | 3 (13.64%) | 4 (1.02%) | <0.0001† | | Metabolic syndrome, n (%) | 8 (36.36%) | 72 (18.37%) | 0.0375 | | Cortisol excess screening, n (%)‡ | 22 (100%) | 392 (100%) | — | | Confirmation test performed, n (%)§ | 22 (100%) | 264 (67.35%) | — | | Aldosterone excess screening, n (%) | 22 (100%) | 392 (100%) | — | | Confirmation test performed, n (%) | 22 (100%) | 392 (100%) | — |
|
|
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HT: hypertension; CVE: cardiovascular events; A/CPA: aldosterone- and cortisol-coproducing adenoma; APA: aldosterone-producing adenoma; ; ; ‡Cortisol excess screening: 0:00, 8:00, 16:00 serum cortisol tests; §Cortisol excess confirmation tests: 24-hour urinary free cortisol test and 1 mg overnight dexamethasone suppression test. |
